Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06890494 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia

StatusRecruiting
PhaseEarly Phase 1
Started2025-01-18
View on ClinicalTrials.gov ↗

Amendment history

2026-03-06
Study Status v1
Re-verified, no change to tracked fields
2025-03-17
Original filing
The goal of this clinical trial is to learn if BiTE-EV works to treat relapsed/refractory acute B-cell leukemia in adults. It will also learn about the safety of BiTE-EV. The main questions it aims to answer are: Can BiTE-EV effectively treat relapsed/refractory acute B-cell lymphoblastic leukemia? What medical problems do participants have when taking BiTE-EV? Participants will: Take BiTE-EV every other day for 1 or 2 months Keep a diary of their symptoms during the medication period During the follow-up period, visit the clinic once every 4 weeks for checkups and tests
Trial Details
NCT Number NCT06890494
Lead Sponsor Beijing GoBroad Hospital
Conditions Leukemia
Enrollment 3 participants
Start Date 2025-01-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10